Takeda’s oral TYK2 inhibitor zasocitinib (TAK-279) showed statistical superiority over Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a top-line Phase 3 Latitude Atlas readout for moderate-to-severe plaque psoriasis. The trial result puts Takeda’s pill into direct competition in a crowded psoriasis therapeutics arena. The Phase 3 head-to-head positioning matters because it tests real-world comparators within the same development context, not cross-trial impressions alone. Takeda is aiming to launch in the first half of 2027 as it seeks to convert efficacy into patient switching from injectable alternatives. For the market, the readout increases pressure on Sotyktu’s momentum and may influence prescriber and payer discussions around oral mechanism-of-action choices in plaque psoriasis.